Related Experiment Video
Updated: Sep 9, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Development of Insulin-Like Growth Factor Mimetic Materials
Abhishek Roy1, Joseph B Dodd-O1, Bobak Shadpoor1
1Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ, 07102, USA.
Abstract:
Growth factors play a crucial role in regulating cellular processes such as proliferation, differentiation, and survival. Their activities are tightly modulated to ensure proper physiological functioning, with dysregulation often contributing to disease pathogenesis. Among these, the insulin-like growth factor (IGF) system that encompasses IGF-1 and IGF-receptor binding proteins is pivotal in maintaining overall cellular health by regulating growth, repair, and metabolic regulation. Capitalizing on its pro-mitogenic effects, translational studies have focused efforts on developing therapeutics based on IGF-1 for age-related muscle loss, metabolic disorders, or cardiovascular diseases. Mimetic peptide design has emerged as an innovative approach to overcoming limitations of direct IGF-1 therapy, focusing on structural optimization to enhance bioavailability, stability, and receptor specificity. Herein, the development of IGF-1 mimics and their potential clinical applications are reviewed. Their design and molecular properties, including structural considerations and mechanisms of action, are described. In vitro and in vivo approaches analyzed to provide insights into their pharmacokinetics, therapeutic efficacy, and safety profiles in animal models will be delved into. These preclinical studies shed light on the advantages of IGF-1 mimics, such as bioavailability, stability, and delivery, as well as the limitations, including potential immunogenicity.
More Related Videos
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
06:33Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells
Published on: February 2, 2024
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Insulin: The Receptor and Signaling Pathways